Ann Rheum Dis 2023; 2023-224762 DOI: 10.1136/ard-2023-224762 Epub ahead of print
The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.
Health Related Quality of Life, Remission and Low Lupus Disease Activity State in Patients with Systemic Lupus Erythematosus
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead407 Epub ahead of print
One of the first studies to investigate associations between disease activity and QoL, using validated generic and disease-specific PRO questionnaires, found that DORIS remission and LLDAS were associated with significant and clinically relevant higher QoL in most PRO domains of the LupusPRO (disease specific) and SF-36 (generic) questionnaires, but not with LupusQoL and SLEQOL disease-specific questionnaires.
New Biologics and Targeted Therapies in Systemic Lupus: From New Molecular Targets to New Indications. A Systematic Review
Joint Bone Spine. 2023.
Systematic review of new biologics and targeted therapies in systemic lupus identifies a highly diversified pipeline of investigational drugs that will hopefully enable a more optimal treat-to-target strategy.
Arthritis Care Res (Hoboken). 2021 Dec 28. Epub ahead of print
Study identifies shifts in the paradigm of systemic lupus erythematosus (SLE) damage and develops a unifying conceptual framework to inform development of a revised SLE Damage Index (SDI).
Shifts in the concept of damage in SLE have occurred with new insights into disease manifestations, diagnostics, and therapy. Consequently, there is a need for a revised SDI, to incorporate additional factors that contribute to damage accrual.